Related Experiment Videos

Inflammatory mediators in Chinese patients with congestive heart failure

Yongqing Wang1, Yanli Zhou, Ling Meng

  • 1Research Division of Clinical Pharmacology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China. wangyq999@yahoo.com.cn

Journal of Clinical Pharmacology
|April 29, 2009
PubMed

Insights

This study investigated inflammatory and anti-inflammatory mediators in Chinese patients with chronic heart failure (CHF). Findings show elevated levels of these mediators and a decreased interleukin-10 to tumor necrosis factor-alpha ratio in CHF patients.

Area of Science:

  • Cardiology
  • Immunology
  • Biochemistry

Background:

  • Chronic heart failure (CHF) is associated with complex pathophysiological changes.
  • Inflammatory and anti-inflammatory mediators play a crucial role in heart failure progression.
  • Understanding these mediators in diverse populations like Chinese patients is important.

Purpose of the Study:

  • To investigate circulating levels of proinflammatory and anti-inflammatory mediators in Chinese patients with CHF.
  • To compare these levels between CHF patients and healthy controls.
  • To examine the relationship between mediator levels and disease severity (NYHA class).

Main Methods:

  • Sixty-five CHF patients and 32 controls were studied.
  • Plasma levels of interleukin-6 (IL-6), IL-10, tumor necrosis factor-alpha (TNF-alpha), atrial natriuretic peptide (ANP), and brain natriuretic peptide (BNP) were measured using immunoradiometric assay kits.
  • Plasma catecholamine (CA) levels were determined by high-performance liquid chromatography.

Main Results:

  • Plasma levels of IL-6, IL-10, TNF-alpha, ANP, BNP, and CA were significantly higher in CHF patients compared to controls.
  • Higher New York Heart Association (NYHA) class correlated with increased concentrations of inflammatory mediators.
  • The ratio of plasma IL-10 to TNF-alpha was significantly lower in CHF patients than in controls.

Conclusions:

  • Proinflammatory and anti-inflammatory cytokine levels are elevated in Chinese patients with CHF.
  • The reduced IL-10/TNF-alpha ratio suggests an altered inflammatory balance in CHF.
  • These findings highlight the role of inflammatory mediators in the pathogenesis of CHF in this population.

Related Concept Videos

Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...